Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Sifalimumab 200 mg
Total, all-cause mortality	Sifalimumab 600 mg
Total, all-cause mortality	Sifalimumab 1200 mg
Total, other adverse events	Placebo	93	108
Total, other adverse events	Sifalimumab 200 mg	94	108
Total, other adverse events	Sifalimumab 600 mg	96	108
Total, other adverse events	Sifalimumab 1200 mg	92	107
Total, serious adverse events	Placebo	19	108
Total, serious adverse events	Sifalimumab 200 mg	16	108
Total, serious adverse events	Sifalimumab 600 mg	22	108
Total, serious adverse events	Sifalimumab 1200 mg	21	107

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01283139/event-totals